Insulet (PODD) | Stock Overview & Key Data
Insulet Performance Comparison
Stock Range
Today's Range
52 Week Range
All-Time High: $335.91 on May 1, 2023
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Financial Highlights
Profitability
Returns and Earnings
Growth
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Insulet PODD | 21.65B Large-cap | -1.16% | -2.99% | 20.03% | 9.67% | 15.44% | 48.88% | 29.46% | 50.40% |
| Abbott Laboratories ABT | 231.85B Mega-cap | -2.13% | -0.03% | 7.59% | 16.73% | 17.56% | 28.29% | 22.86% | 34.71% |
| Boston Scientific BSX | 149.87B Large-cap | -2.26% | 2.37% | 12.99% | 6.73% | 14.58% | 33.65% | 176.51% | 175.34% |
| Stryker SYK | 147.95B Large-cap | -1.82% | 1.89% | 15.45% | 6.98% | 8.58% | 15.66% | 101.54% | 103.32% |
| Medtronic plc MDT | 110.29B Large-cap | -0.19% | 1.29% | 8.18% | 7.14% | 10.42% | 12.47% | -1.63% | -11.07% |
| Edwards Lifesciences EW | 43.31B Large-cap | -1.02% | 0.04% | 13.90% | 3.02% | 5.23% | -15.72% | -22.87% | 3.48% |
Ownership & Short Interest
Insulet Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Insulet would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
In the last 52 weeks, Insulet reached a high of $329.33 (on May 21, 2025) and a low of $173.00 (on August 9, 2024).
Curious about Insulet's size and valuation? Its market capitalization stands at 21.65B. When it comes to valuation, the P/E ratio (trailing twelve months) is 55.44, and the forward P/E (looking ahead) is 79.50.
As for dividends, Insulet isn't currently offering a significant yield, or that specific data isn't available right now.
When looking at Insulet, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Abbott Laboratories
ABT231.85B Healthcare Medical Devices 28.29% 22.86% Boston Scientific
BSX149.87B Healthcare Medical Devices 33.65% 176.51% Stryker
SYK147.95B Healthcare Medical Devices 15.66% 101.54% Medtronic plc
MDT110.29B Healthcare Medical Devices 12.47% -1.63% Edwards Lifesciences
EW43.31B Healthcare Medical Devices -15.72% -22.87% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
To get a sense of Insulet's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 37.92%, the Debt to Equity ratio from the most recent quarter is 131.41, and its Gross Profit Margin stands at 71.88%.
Looking at Insulet's growth, its revenue over the trailing twelve months (TTM) was $2B. Compared to the same quarter last year (YoY), quarterly revenue grew by 28.80%, and quarterly earnings saw a YoY growth of -31.30%.
Wondering who owns Insulet stock? Company insiders (like executives and directors) hold about 0.29% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 102.73%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.